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Abstract 
Atherosclerosis is the leading cause of cardiovascular diseases like myocardial infarctions and 
strokes. The formation of these atherosclerotic plaques occurs through localized inflammatory 
responses in blood vessels.  Epidemiological evidence suggests omega-3 fatty acids (FAs) 
decrease vascular inflammation. The omega-3 FAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) reduce inflammation through pathways that may include the free 
fatty acid-4 (FFA-4) receptor.  While EPA and DHA are well studied, less is known about the 
essential omega-3 FA from which they are synthesized: alpha-linolenic acid (ALA). Thus, this 
study will investigate whether ALA can activate the FFA-4 receptor and thereby contribute to 
anti-inflammatory responses in the endothelium.  Although the FFA-4 receptor is a G-protein 
coupled receptor, its activation reduces the nuclear transcription factor NF-κB thereby decreasing 
the synthesis and release of inflammatory cytokines. The resulting decrease in inflammatory 
cytokines is expected to decrease expression of connexin-43 (Cx43).  Cx43 is a gap junction 
protein whose endothelial cell expression is increased during inflammation contributing to an 
unhealthy endothelium.  Treatment of endothelial cells with 30 M ALA is hypothesized to 
decrease the expression of Cx43 through the activation of the FFA-4 receptor.  Cultured mouse 
endothelial cells (bEnd.3) were treated with physiological ALA concentrations (30 M) for 48 
hours. Whole-cell protein was isolated from treated and controlled endothelial cells at 1.5, 3, 6, 
12, 24 and 48 hours and expression of Cx43 determined.  Over the 48 hours of ALA exposure, 
Cx43 expression did not change (ratio of Cx43 expression in ALA treated/time-control was not 
different from 1: p>0.05).  Increasing ALA to 100 M did nothing to affect Cx43 expression in 
cells at 12 – 48 hours (p>0.05).  While this suggests ALA is not involved in omega-3 FA 
dependent anti-inflammatory responses in the endothelium, these results could be affected by 
 5 
ALA activating the pro-inflammatory FFA-1 receptor.  However, treatment of cells with 10 M 
GW-9508 (selective FFA-1 receptor agonist) did not affect Cx43 expression at 48 hours 
(p>0.05).  Thus, treatment of bEnd.3 cells with ALA did not alter expression of Cx43. These 
results suggest ALA may not contribute to the anti-inflammatory influence omega-3 FAs exert 
on endothelial cells. 
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Chapter 1: Introduction 
Cardiovascular disease (CVD) is the leading cause of deaths worldwide accounting for 
over 17.7 million (WHO, 2015) and costing the world economy nearly $475 billion (Ahmad et 
al., 2018 and Adkins et al., 2010).  A majority of these deaths are due to heart attacks and strokes 
(WHO, 2015), which are caused by atherosclerotic changes in the vascular wall.  Atherosclerotic 
changes are characterized by a stiffening and narrowing of the arteries due to a chronic, low 
grade inflammatory response (Gu et al., 1998 and Libby, 2002).  This inflammatory response is 
initiated by damage to the endothelium allowing circulating low density lipoproteins (LDLs) to 
migrate into the underlying smooth muscle layer (Stoll et al., 2006).  These LDLs are oxidized 
and ingested by macrophages releasing inflammatory cytokines to recruit other immune cells 
(Stoll et al., 2006).  Those cytokines also turn contractile smooth muscle cells into secretory cells 
releasing the collagen which drives the inward growth of the plaque.  The macrophages in the 
center of the plaque continue to ingest LDL molecules until they become foam cells and die.  
This results in the formation of a necrotic core in the plaque that weakens it (along with matrix 
metalloproteinases released by immune cells) causing plaques to become unstable.  The shearing 
forces of the blood break the plaque free from the vessel wall and occlude smaller arteries of the 
coronary and cerebral circulation (Stoll et al., 2006, Calder, 2013, Kris-Etherton, 2002, and 
Kwak et al., 2002).  The exposed necrotic core is rife for platelet aggregation resulting in 
thrombus formation.  This thrombus has the potential to be sheared free by the blood to occlude a 
larger vessel in comparison to the vessel occluded by the plaque, further resulting in a heart 
attack or a stroke.  While some individuals develop clinically relevant complications from this 
process, these plaques form in all humans at different rates that are impacted by risk factors. 
Thus, we all have the potential for the development of CVDs. 
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One of the initial steps in atherosclerotic plaque development involves LDL particles 
migrating into the smooth muscle layer.  LDL particles circulate in the blood transporting lipids 
in a membrane bound structure (with proteins embedded in the phospholipid membrane).  One 
type of lipid within the LDL particle is a triacylglycerol which is composed of 3 fatty acids (FA) 
and a glycerol molecule.  Those FAs are released by lipoprotein lipases in the vessel wall (Mead 
et al., 2002) and become free FAs.  FAs are composed of 3 types of carbon-carbon bonds: trans 
or cis (stereoisomers), saturated (no double bonds) or unsaturated (1 or more double bonds).  
While consumption of trans and saturated FAs increases the risk for developing CVDs (Pietinen 
et al., 1997 and Wang et al., 2017), unsaturated FAs (specifically Omega-3s) decrease the risk 
for developing CVDs (Wang et al., 2017, Schmidt, 1997, Nair et al., 1997, William-Bey et al., 
2014, and Rodriguez-leyva et al., 2010).  There are 3 omega-3 FAs proposed to decrease the risk 
of CVD: alpha-linolenic acid (ALA, 18 carbon), eicosapentaenoic acid (EPA: 20 carbon), and 
docosahexaenoic acid (DHA, 22 carbon).  Their anti-inflammatory properties are mediated by a 
number of pathways including reduced production of inflammatory cytokines (Mohebi-Nejad et 
al., 2014), reduced expression of endothelial cell and platelet adhesion molecules (Mozaffarian et 
al., 2011), decreased acute phase reactants (Adkins et al., 2010), and the ability to bind to nuclear 
receptors including peroxisome proliferator activating receptors (PPARs: Adkins et al, 2010) and 
hepatocyte nuclear factor-4 alpha (HNF-4a: Adkins et al., 2010).  More recently, the discovery of 
G-protein coupled free FA receptors (FFAs), which can also act as nuclear receptors, has spurred 
interest in their role of impacting CVDs.   
The FFA receptor superfamily includes four members: FFA-1 through FFA-4 (Oh et al., 
2014).  The FFA-2 and FFA-3 receptors are stimulated by short chain FAs (carbon backbone 
length of 2-6 carbons: propionate, butyrate, acetate, etc.) and are expressed exclusively within 
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entero-endocrine cells (Nøhr et al., 2013). The FFA-1 and FFA-4 receptors are stimulated by 
long chain FAs (carbon backbone of 12 to 22 carbons: palmitic, oleic, etc.) including both 
saturated and unsaturated FAs like the omega-3s (Nøhr et al., 2013).  Expression of the FFA-1 
receptor has only been observed in the human pancreas and intestinal entero-endocrine cells 
(Ichimura et al., 2014).  The FFA-1 receptor activation increases secretion of intestinal hormones 
(Ichimura et al., 2014) and increases inflammation, however, the mechanism of action has yet to 
be determined (Cheshmehkani et al., 2015 and Mena et al., 2016).  In contrast, the FFA-4 
receptor is ubiquitously expressed throughout the body (Cheshmehkani et al., 2015, Oh et al., 
2014, and Ichimura, et al, 2014). The FFA-4 receptor can be stimulated by the omega-3 FAs and 
the receptor mechanism of action, promoting an anti-inflammatory response, has been studied 
and illustrated (Denis et al., 2017, Oh et al., 2014, Williams-Bey et al., 2014 and Cheshmehkani 
et al., 2015). Once the FFA-4 receptor is activated, it interrupts the signaling for the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) translocation into the nucleus 
(Oh et al., 2014, Cheshmehkani et al., 2015, Denis et al., 2017, and Nøhr et al., 2013).  NF-κB is 
a transcription factor responsible for the production of pro-inflammatory cytokines including 
interleukin-6 (IL-6), IL-1, and TNF- (Williams-Bey et al., 2014).  Inhibition of NF-κB 
translocation by the FFA-4 receptor would reduce inflammation by decreasing pro-inflammatory 
cytokine release. 
Exposure of the endothelium to inflammatory cytokines affects cell to cell 
communication by altering gap junction protein expression (Brisset et al., 2009).  Gap junctions 
are composed of a connexon (6 connexin (Cx) proteins) that forms a hemi-channel in the cell 
membrane.  When these connexons from neighboring cells come into contact, they form a 
complete channel for communication of signals including the exchange of metabolites, ions, and 
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other messenger molecules between cells (Brisset et al., 2009 and Kwak et al., 2002). Each 
connexin isoform has a unique permeability to signaling molecules and, thus, a different message 
sent. There are three Cx isoforms in endothelial cells including Cx37, Cx40, and Cx43 (Kwak et 
al., 2002).  Healthy endothelial cells express many Cx37 and Cx40 (Brisset et al., 2009), 
however, Cx43 is mainly restricted to smooth muscle cells (Kwak et al., 2002).  When 
inflammation is present within the endothelium and there is an increased expression of NF-κB, 
not only are inflammatory cytokines released, but NF-κB has been shown to increase the 
expression of Cx43 on the cell surface as well.   NF-κB translocation into the nucleus has been 
found to bind directly to the promoter of the Cx43 gene (Alonso et al., 2010).  As NF-κB is a 
pro-inflammatory transcription factor, associated with regions of inflammation in the 
endothelium (i.e. atherosclerotic plaques), and is responsible for the increased expression of 
Cx43 on endothelial cells, Cx43 can be used as an indicator of inflammation and poor 
cardiovascular cell health (Brisset et al., 2009, Kwak et al., 2002, and Puebla et al., 2017) 
ALA is the essential omega-3 FA (Rodriguez-Leyva et al., 2010) and therefore must be 
consumed in the diet (Kris-Etherton et al., 2002).  In the liver, ALA is exposed to desaturase and 
elongase enzymes, which adds carbon atoms to ALA resulting in the synthesis of EPA and DHA 
(Calder, 2013).  ALA binds to the FFA-4 receptor in entero-endocrine cells and stimulates the 
secretion of cholecystokinin and glucagon like peptide 1 (Hirasawa et al., 2005).  If this receptor 
is expressed in the endothelium, ALA should activate the FFA-4 receptor and stimulate an anti-
inflammatory response within the endothelium.  Since the FFA-4 receptor is expressed in many 
different cells including bEnd.3 mouse cultured endothelial cells (Rogers and Kurjiaka: Personal 
communication), treating these cells with physiological concentrations of ALA should initiate an 
anti-inflammatory response through FFA-4 receptor activation.  If activation of the FFA-4 
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receptor generates an anti-inflammatory response in the endothelium via inhibition of NF-κB 
translocation into the nucleus, we would expect the expression of Cx43 to also decrease.  We 
hypothesize that treating cultured endothelial cells (bEnd.3) with ALA will decrease Cx43 
expression as an indication of their anti-inflammatory response, thus increasing endothelial cell 
health.  As the duration of FFA-4 receptor activation required to alter Cx43 expression has yet to 
be determined, we will evaluate the response of bEnd.3 cells to 30 M ALA from 1.5 to 48 hours 
of treatment.   
Purpose: 
 Cardiovascular disease is one of the leading causes of death worldwide.  Many of these 
diseases are the results of the development of atherosclerotic plaques within the arterial walls due 
to the presence of a chronic low grade inflammatory response.  Omega-3 FA consumption has 
long been reported to decrease the risk of CVDs.  This appears to be due in part to their ability to 
decrease inflammation in general as well as within atherosclerotic plaques.  The purpose of this 
research is to determine whether this anti-inflammatory response in the endothelium can be 
mediated by the plant-based essential omega-3 FA, ALA.  This evidence would support efforts to 
reduce atherosclerotic plaques.  If ALA can also decrease inflammation within the endothelium, 
there may be another method for the prevention and/or treatment of atherosclerosis and 
subsequent CVD. 
Scope: 
This experiment is being completed on a mouse endothelial cell culture (cell line bEnd.3) 
purchased from American Tissue Culture Collection (ATCC). 
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Assumptions: 
Vascular endothelial cells are usually quiescent (not in the cell cycle), only proliferating 
in response to damage/inflammation.  However, bEnd.3 cells are immortalized mouse 
endothelial cells that are proliferating in an uncontrolled manner.  Even the removal of serum 
does not stop this proliferation.  With that said, these cells do express the FFA-4 receptor and the 
downstream signaling pathway.  Therefore, these endothelial cells should respond to 
physiological concentration of ligand (ALA) by altering Cx43 expression. 
Hypothesis: 
 Omega-3 FAs, such as EPA and DHA, stimulate anti-inflammatory responses upon 
activation of the FFA-4 receptor (Williams-Bey et al., 2014, Oh et al., 2014, and Hirasawa et al., 
2005).  ALA is the essential omega-3 FA and has been shown to activate the FFA-4 receptor, 
however, not within the endothelium.  If the FFA-4 receptor is present within the endothelium, 
ALA should render it activated, decrease NF-κB translocation into the nucleus, and decrease the 
expression of Cx43 on endothelial cells, thereby reduce inflammation.  Therefore, ALA 
stimulation on bEnd.3 endothelial cells is hypothesized to activate the FFA-4 receptor and 
decrease the expression of Cx43, thereby decreasing inflammation and increasing endothelial 
cell health.  
Significance: 
Due to the millions of people around the world impacted by CVDs and their economic 
consequence, developing a better understanding of the mechanisms by which omega-3 FAs 
reduce inflammation, and thereby CVDs, is very important.  Results from this study may present 
additional avenues for drug development in the area of the FFA-4 receptor agonist to take 
advantage of the downstream consequence of its activation.  At the same time, they provide 
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people with reasons to adjust their diet to take advantage of the positive effects of the omega-3 
FAs on their cardiovascular health. 
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Chapter 2: Review of Literature 
Cardiovascular Disease: CVD continues as the leading cause of death in the United States 
accounting for 36% of those recorded (WHO, 2015). Most CVDs result from blockage of 
coronary and cerebral arteries by atherosclerotic plaques leading to myocardial infarctions and 
strokes (respectively). The resulting impact of these CVDs on the US economy is substantial 
accounting for an estimated $475 billion ((Ahmad, et al., 2018 and Adkins et al, 2010). The 
extent of the economic costs to the US make it essential we understand the factors impacting the 
development and progression of these plaques. 
 Atherosclerosis:  Atherosclerotic plaques develop (Figure 1) as a localized inflammatory 
response in the arterial wall (Nair et al., 1997).  These plaques start as fatty streaks generated by 
damage to the overlying endothelium (Stoll et al., 2006).  Circulating LDL particles begin to 
accumulate in these damaged sites and become oxidized (oxLDL), stimulating the release of 
inflammatory cytokines from endothelial cells (EC: Adkins et al, 2010) including interleukin 6 
(IL-6), IL-1, and TNF-α (Williams-Bey et al., 2014).  These inflammatory cytokines stimulate 
EC expression of adhesion molecules including P-selectin and vascular cell adhesion molecules 
(VCAMs), which recruit monocytes to the site of damage (Calder, 2004). There, monocytes 
differentiate into macrophages that absorb the accumulating oxLDL to the extent that they turn 
into foam cells.  These foam cells then die leaving the core of the plaque to become necrotic 
(Stoll et al., 2006).  At the same time, more cytokines are released to recruit additional 
leukocytes, (e.g., T cells) which stimulate the overlying smooth muscle cell (SMC) to migrate 
inward, proliferate, and secrete collagen to form the fibrous cap of the plaque (Libby, 2002).  
These recruited T-cells act on the plaque by inhibiting SMC collagen secretion and stimulate the 
release of additional cytokines, collagenases, and matrix metalloproteinases that destabilize the 
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plaque (Libby, 2002 and Stoll et al., 2006). These unstable plaques are at risk of rupturing, 
releasing the overlying cap, and occluding small vessels downstream. The rupture of the fibrous 
cap exposes the necrotic core which causes platelet aggregation and thereby thrombus formation 
(Stoll et al., 2006).  The thrombus can grow large enough that when it breaks free, a larger 
vessel, compared to the vessel occluded by the plaque, will become occluded. This occlusion 
poses the potential for causing a myocardial infarction or stroke (Kris-Etherton, 2002 and 
Eritsland et al., 1996), potentially leading to death. 
 
Figure 1: The Development of atherosclerosis.  Atherosclerosis begins with the damaged endothelium from an external source 
and ends with potential thrombus formation.  Note that the thrombus being formed in this image is due to a previous event where 
the unstable plaque broke free.  The thrombus being formed has the potential to break free due to hemodynamic forces and 
induce a fatal MI or stroke (Madamanchi, 2004).  
 
Dietary Fatty Acids:  Plaque development within an artery is a dynamic process involving 
multiple factors.  One of the most important influences on this process is diet, specifically, the 
consumption of dietary fats.  Epidemiological evidence dating back to the 1970’s links free FAs 
to plaque development (Dyerberg, 1978).  FAs provide many diverse functions from energy 
storage to being a signaling molecule (prostaglandin and leukotriene synthesis: Egert et al., 
2007).  FAs are composed of a hydrocarbon chain with a hydrophobic methyl group on one end 
(omega end) and a hydrophilic carboxyl group at the opposite end (delta end: Schmidt, 1997).  
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FAs are defined by the extent and type of 
double bond(s) along its length from 
saturated (no carbon double bond) to 
unsaturated (at least one double bond).  
Unsaturated FAs are further divided by the 
type of double bond: a cis-unsaturated 
double bond adds a kink along its length 
whereas trans-unsaturated FAs have 
undergone partial hydrogenation, which 
straightens the FA (Figure 2: Lichtenstein, 
2016).  This partial hydrogenation process allows trans-FAs to pack tightly together and will 
remain in the body for an extended period of time as it is not readily available for energy 
production (Mozaffarian et al., 2007).  Not only are these trans-FAs a poor source for energy, but 
they also bind to the toll like receptor 4 (TLR-4) to stimulate inflammation (Harper et al., 2001).   
Polyunsaturated FAs are further distinguished by the location of the first cis double bond: 
omega-3 (double bond on the third carbon from omega end) and omega-6 (double bond located 
on the sixth carbon: Roche, 1999).   Alpha-linolenic acid (ALA) is the essential omega-3 FA and 
is the precursor for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  This 
synthesis involves desaturase and elongase enzymes (Figure 3: (Pereira, 2004 and Calder, 2013).  
Linoleic acid is the essential omega-6 FA converted by the same desaturase and elongase 
enzymes (Pereira et al., 2004) into arachidonic acid (AA: figure 3).  Arachidonic acid is a 
precursor for prostaglandin synthesis (Pereira et al., 2004 and Calder, 2013), which would 
influence inflammation.  The body’s response to these FAs is affected by the degree of 
Figure 2: Trans-FA structure in comparison to a cis-FA 
structure.  Note the kinked formation associated with the 
double bond in the cis-FA structure (Left: Oleic acid).  The 
trans-FA (Right: Elaidic acid) has a double bond in the trans 
configuration rendering it linear (Lichtenstein, 2016) 
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unsaturation (mono vs polyunsaturated: Roche, 1999), the first carbon unsaturated (omega-3 vs 
omega-6:  Pischon, 2003) and its stereoisomeric structure (cis- or trans-unsaturated: Roche, 
1999).  Depending on these factors which influence FA structure within our diet, inflammation 
can be altered within our vessels leading to an increase or decrease in the progression of 
atherosclerosis.  
 
  
Figure 3: The conversion of omega-6 and omega-3 FAs in the body:  The enzymes involved in both the conversion of omega-
3's and omega-6's are the same, suggesting competition in conversion of FAs.  Note the inflammatory effects of the omega 6 FA 
contrast that of the omega-3 FA (Calder, 2013).  
  
 Omega-3 Fatty Acids:  The anti-inflammatory effects of omega-3 FAs were first suggested by 
studies on Greenland Eskimos (Dyerberg, 1978).  Despite their high fat diet, including seal meat 
and whale blubber, incidence of myocardial infarctions and strokes were much lower in Eskimos 
than expected (Dyerberg, 1978).  This was later attributed to their higher omega-3 FA diet (fish 
oils: EPA and DHA).  Consumption of these omega-3 FAs markedly decreased triglycerides 
within their circulation by 34% (Dyerberg, 1978).  Similar reductions in CVD risk in Japan and 
 22 
the Netherlands (regions with high omega-3 consumption) supported the positive effects of 
omega-3’s on human health (independent of activity and other risk factors: Yano et al., 1988 and 
Kromhout et al., 1985).  This has spurred an effort to understand how omega-3 FAs reduce CVD 
risk.  To date, omega-3 FAs have been shown to reduce inflammation by decreasing leukocyte 
chemo-attraction (Sperling et al., 1993), inflammatory cytokine expression (TNF-, IL-1B and 
IL-6: Calder, 2013), EC adhesion molecule expression (Collie-Duguid et al., 1996), platelet 
adhesion, and platelet aggregation (Calder, 2004).  Specifically, the reductions in platelet 
aggregation and adhesion increase the stability of late stage plaques (Calder, 2004). These 
reductions in inflammatory mediators are thought to occur via inhibition of the NF-κB cell 
signaling pathway (Calder, 2013). 
 Inflammation via NF-κB:  NF-κB is primarily an inflammatory signaling molecule, which 
translocates into the nucleus and increases the expression of pro-inflammatory genes.  These 
genes result in the increased production of cytokines, chemokines, cell surface adhesion 
molecules, and gap junction proteins, further increasing inflammation (Williams-Bey et al., 
2014, Oh et al., 2014 and Denis et al., 2017).  NF-κB can be activated by reactive oxygen 
species, TNFα, lipopolysaccharides (LPS), and saturated FAs (Williams-Bey et al., 2014).  
Specifically, LPS and saturated FAs bind to the toll like receptor 4 (TLR-4) to elicit a pro-
inflammatory response (Williams-Bey et al., 2014).  Thus, any changes in inflammatory 
responses are likely to involve alterations in the NF-κB cell signaling pathway. 
Free Fatty Acid Receptors:  The mechanism by which omega-3 FAs (or any other anti-
inflammatory mediators) reduce NF-κB signaling could involve reductions in TLR-4 activation 
or activation of another signaling pathway.  While saturated FAs and LPS bind to TLR-4, 
omega-3 FAs do not antagonize this physical interaction (Oh et al., 2014).  Rather, they reduce 
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NF-κB by binding to free FA receptors (FFA).  Four isoforms of these de-orphaned receptors 
were identified [FFA-1 (GPR40), FFA-2 (GPR43), FFA-3 (GPR41), and FFA-4 (GPR120)].  
Each FFA receptor is coupled to a different signaling pathway: some have anti and others pro-
inflammatory effects (Williams-Bey et al., 2014 and Cheshmehkani et al., 2015).  FFA-2 and 
FFA-3 receptors bind to short chained FA (fewer than 6 carbons: Ichimura et al., 2014), whereas 
the FFA-1 and FFA-4 receptors bind to long chained FA (more than 12 carbons: refer to figure 4: 
Ichimura et al., 2014), including all omega-3 FAs (Figure 4: Ichimura et al., 2014 and 
Cheshmehkani et al., 2015).  Although omega-3 FAs bind to FFA-1 and FFA-4 receptors, the 
FFA-1 receptor is only expressed in the pancreas and entero-endocrine cells, contrasting the 
broader expression of the FFA-4 receptor in tissues including the lungs, macrophages, intestines, 
and endothelial cells (Ichimura et al., 2014, Oh et al., 2014, and Nøhr et al., 2013).  The FFA-4 
receptor was shown to reduce inflammation (Oh et al., 2014 and Williams-Bey et al., 2014) by 
interrupting NF-κB translocation (Cheshmehkani et al., 2015).  
 
          FFAR1  FFAR4 
 
 
Figure 4: Unsaturated FA structure and its affinity to bind to FFA-1/4 (Ichimura et al., 2014).  All the omega-3 FAs show 
the ability to bind to both the FFA-4 as well as the FFA-1.  The FFA-receoptors shown on the right coorelate with the FA of 
interest directly to the left.  A plus sign (+) indicates the affinity of the FA to the FFA-receptor.  A single (+)  is indicative of a 
slight affinity to the receptor while three (+)’s is indicative of having high affinity.  Note the location of the receptors vary 
throughout the body and could produce different effects. 
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Free Fatty Acid 4 Receptor:  The FFA-4 receptor has potential to reduce NF-κB signaling in 
many tissue types (i.e., macrophages, heart, lungs, GI tract, and vasculature: Cheshmehkani et 
al., 2015) due to its diverse expression.  The mechanism of action involves the activated FFA-4 
receptor binding to -arrestin-2 which internalizes and inhibits TAB1 activation (an adaptor 
protein for the pro-inflammatory kinase TAK-1: Denis et al., 2017).  TAK-1 is thereby prevented 
from initiating NF-κB translocation (Figure 5: Oh et al., 2014, 2014, Williams-Bey et al., 2014, 
and Cheshmehkani et al., 2015).  Thus, activation of the FFA-4 receptor reduces pro-
inflammatory cytokine production (Williams-Bey et 
al., 2014) via inhibition of NF-κB translocation.  
Although this response was demonstrated in 
macrophages (Williams-Bey et al., 2014 and 
Hirasawa et al., 2005), a similar signaling response 
has yet to be reported in endothelial cells. 
         Endothelial cell NF-κB is activated by many 
factors including bacterial and viral infections (Pahl, 
1999), LPS activation of TLR-4 (Williams-Bey et al., 
2014), and oscillating shear stress (Denis et al., 
2017).  Increases in endothelial cell NF-κB activation increases the release of cytokines and 
chemokines (Pahl, 1999), alters cell surface protein expression (including VCAMs: Oh et al., 
2014), and alters vascular connexin expression (Brisset et al., 2009). 
Connexins: Connexin (Cx) proteins are embedded in the cell membrane as hexamers to form 
connexon hemi-channels (Brisset et al., 2009) that couple with hemi-channels in neighboring 
cells allowing cell-to-cell communication.  The permeability and gating of these channels is 
Figure 5: FFA-4 receptor mechanism of action 
when stimulated. Stimulation may occur by omega-3 
FAs or synthetic agonist.  Normal TLR-4 activation 
and NF-kB translocation is inhibited (Oh et al., 2014) 
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determined by the specific connexins that comprise the channels.  (Figure 6: Kumar et al., 1996). 
Of the 21 Cx isoforms expressed in mice (Brisset et al., 2009), 3 main Cxs are expressed in the 
vascular wall: Cx37, Cx40 and Cx43 (Puebla et al. 2017).  
 
Figure 6: Connexin (Cx) topological molecular models (A): Topological model of a connexin illustrating the 4 trans-
membrane domains with 2 extracellular loops (E1 and E2) influencing hemi-channel docking, located extracellularly. (B) Gap 
junction model: 6 individual Cx proteins arranged in an oligomeric arrangement to form a hemi-channel coming into contact with 
a neighboring cell.  The adjacent cells dock to one another via the extracellular loops and form a communicatory pore with 
varying selectivity; a gap junction (Kumar et al., 1996).  
 
Healthy endothelial cells are preferentially coupled by Cx37 and Cx40 (Brisset et al., 2009, 
Kwak et al., 2002, and Denis et al., 2017).  Cx43, in normal physiological conditions, is 
restricted to expression in healthy smooth muscle cells and not on the endothelium (Kwak et al., 
2002).  However, within the presence of NF-κB along with the inflammatory cytokines released, 
Cx43 expression lining the endothelium is increased at the shoulders of the developing plaque 
and at sites of oscillating shear stress (Figure 7: Brisset et al., 2009).  NF-κB translocation into 
the nucleus has been found to bind directly to the promoter of the Cx43 gene and increase its 
expression (Alonso et al., 2010).  Since NF-κB is expressed within an inflammatory environment 
(Williams-Bey et al. 2014 and Pahl, 1999) and increases the expression of Cx43 (Alonso et al., 
2010) within the endothelium, indicating inflammation and plaque development, Cx43 protein 
expression will be used as a marker and assayed as an indication of inflammation within the 
vessel wall.   
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Figure 7: An advanced atheroma and Cx expression: The lesion underlying the endothelium consists of the fibrous cap and 
the necrotic core.  The fibrous cap is composed of SMC and collagen while the necrotic core is filled with foam cells, migrating 
SMC, LDL particles, and debris.  The endothelium covering the lesion is composed of increased expression of Cx43 on the 
shoulders and a decreased expression of Cx37 and Cx40 due to inflammatory cytokines (Brisset et al., 2009).   
  
Alpha-Linolenic Acid:  ALA is the essential omega-3 FA and is considered an important 
component of many “superfoods” including chia, flax, and hemp seeds (Egert et al., 2007).  
Previous studies established that fish oil omega-3’s (EPA and DHA) are anti-inflammatory.  
However, it has yet to be determined if ALA elicits anti-inflammatory properties the same as the 
fish oils.  While ALA has been shown to decrease CVD prevalence (Rodriguez et al., 2010) , the 
mechanism by which this occurs has yet to be determined. Through previous studies, among all 
FAs, the FFA-4 receptor is most potently activated by ALA within the gastrointestinal tract 
(Hirasawa et al., 2005).   
Cultured endothelial cells express more Cx43 than they do in vivo (Alonso et al., 2010 
and Kwak, 2003). This suggests that these cultured cells are in a chronically inflamed state with 
elevated activation of NF-κB genes driving the elevation in Cx43 expression.  Since cultured 
endothelial cells express the FFA-4 receptor (Rogers & Kurjiaka: personal communication), 
activation of the FFA-4 receptor upon binding of ALA should reduce NF-κB gene activation (Oh 
et al., 2014 and Williams-Bey et al., 2014) and thereby decrease Cx43 expression.  Thus, we will 
evaluate the impact of the FFA-4 receptor activation on endothelial cell expression of Cx43 
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when treated with ALA.  Stimulation of 30 M ALA on bEnd.3 endothelial cells is hypothesize 
to decrease Cx43 expression.  Previous data from other omega-3 FA experiments suggest the 
change in Cx43 expression would occur at 12-24 hours after ALA treatment is initiated.  Since 
ALA response can be different from other omega-3 FAs, expression was evaluated at 1.5 – 48 
hours after treatment. 
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Chapter 3: Methodology: 
Cell Culture: Cultured mouse endothelial cells (bEnd.3) were purchased from ATCC (American 
Tissue Culture Collection) and maintained (and grown) in high glucose Dulbecco’s modified 
eagle’s medium (HG-DMEM: Thermo Scientific D6429) supplemented with 10% fetal bovine 
serum (FBS: Atlanta Biologicals) and antibiotics (streptomycin and penicillin: Sigma: P4333). 
Cells were grown on 100 mm plates in an incubator at 100% humidity, 5% CO2, and 38°C.  New 
media was added every 2-6 days, depending on cell confluency, to provide cells with adequate 
nutrients and energy for proliferation. To split cells into a plate where they can continue to 
proliferate, the media was aspirated and replaced with 10 mL of a calcium free phosphate 
buffered saline (PD in mM: 137 NaCl, 2.7 KCl, 1.8 KH2PO4, 10 Na2HPO4). PD was then 
aspirated and replaced with 3 mL of 0.25% Trypsin and 0.1% EDTA in PD (TV: Thermo 
Scientific: 2520056).  The TV was aspirated and plates placed into the incubator.  After the cells 
had lifted from the plate, the activity of the TV was stopped by adding 10% FBS HG-DMEM 
and cells from multiple plates were collected in a sterile tube (50 mL centrifuge tube).  After 
thoroughly mixing the cells, they were evenly distributed into 13 plates.  Cells were allowed to 
proliferate in the incubator for 48 hours before being treated with ALA (see experiments below).  
In later experiments, cells that were collected were then counted with a hemocytometer (10 l of 
mixed solution pipetted into the hemocytometer).  800,000 cells were added to each plate.   
Endothelial cell response to 30 M ALA: First, a stock ALA solution of 30 mM was prepared 
by adding ALA (Nu-Chek: U-62A) to 100% ethanol. A 1:1000 dilution of stock ALA was added 
to 10% FBS HG-DMEM for a 30 M ALA solution. The media was aspirated from 12 plates 
and 6 of those treated with the 30 M ALA media and another 6 with 0.1% ethanol in the media 
(controls).  Protein was isolated immediately from the 13th plate (time zero control: method for 
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protein isolation described below).  Thereafter, protein was isolated from a treatment and control 
plate after 1.5, 3, 6, 12, 24, and 48 hours.    
Endothelial cell response to 100 M ALA: A stock ALA solution of 100 mM was prepared by 
adding the ALA to 100% ethanol. A 1:1000 dilution of stock ALA was added to 10% FBS HG-
DMEM for a 100 M ALA solution. The media was aspirated from 7 plates and 3 of those 
treated with the 100 M ALA media and another 3 with 0.1% ethanol in the media (controls).  
Protein was isolated immediately from the 7th plate (time zero control).  Thereafter, protein was 
isolated from a treatment and control plate after 12, 24 and 48 hours. 
Endothelial cell response to 10 M GW-9508 (FFA-1 receptor agonist): A stock agonist (FFA-
1 receptor agonist) solution of 10 mM was prepared by adding GW-9508 (Tocris: 2649) to 100% 
ethanol.  A 1:1000 dilution of stock GW-9508 was added to 10% FBS HG-DMEM for a 10 M 
solution. The media was aspirated from 3 plates and 1 of those plates treated with the 10 M 
GW-9508 media and another plate treated with 0.1% ethanol in the media (control).  Protein was 
isolated immediately from the 3rd plate (time zero control).  Thereafter, protein was isolated from 
a treatment and control plate after 48 hours. 
Protein Isolation/Concentration: Cells were first washed with ice cold phosphate buffered 
saline (PBS in mM: 137 NaCl, 2.7 KCl, 1.7 Na2HPO4, 6.5 NaH2PO4, 1 CaCl2, and 0.5 MgCl2) to 
remove secreted proteins.  The cells were scraped from the surface of the plate and pipetted into 
a 1.5 mL centrifuge tube and centrifuged (Eppendorf 5424 R, 7500 rpm, at 4°C for 5 minutes) to 
form a cell pellet.  The supernatant was aspirated and about 30 L (volume dependent on the size 
of the pellet) of Laemmli sample buffer (32.9 mM Tris HCl, 1.1% SDS, 13% glycerol, 0.01% g 
bromophenol blue, pH of 6.8) was added.  The tube was then sonicated on ice for 30 seconds 
(Misonix XL-2000 series) before the membrane fragments were pelleted by the final 
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centrifugation (15000 rpm at 4°C for 10 minutes).  Those samples were then stored in the freezer 
at -20°C.  Protein concentration was determined using the BCA assay (Thermo Scientific: 
23225) and following the manufacturer’s protocol. Each protein sample was diluted with sample 
buffer to make a 2 g/L solution.  mercaptoethanol was applied (10% sample volume) to 
reduce the proteins and the samples were boiled at 100°C for 5 min (Fisher Scientific: Dry Bath 
Incubator) before being placed in the freezer (-20°C).   
Western Blot Analysis of Cx43 Expression: 
Gel Electrophoresis: Running buffer (25 mM Tris, 192 mM glycine, and 0.1% SDS, pH 
8.3) was first prepared from a 20X stock solution. The antioxidant (Na Bisulfite) was added to 
the Running buffer for a 5 mM solution. Two 4-20% gradient SDS-polyacrylamide gel (Sigma: 
PCG2016) were placed in a gel electrophoresis cassette and the cassette placed within the tank.  
Running buffer with 5 mM Na Bisulfite was added to the inside of the cassette and the 17 wells 
thoroughly rinsed.  Equal volumes of the 2 g/L sample (5 L for 10 g/well) were pipetted 
into each well along with a pre-stained, low molecular weight ladder (Thermo Scientific: PI 
26616).  Running buffer was added to the tank and the gel ran at 200 V (180 mA: E-C Apparatus 
Corporation: EC570-90) for 30-45 minutes to ensure protein separation.   
Protein transfer: Transfer buffer (25 mM Tris base, 192 mM glycine, and 20% methanol) 
was first prepared from a 20X stock solution. A piece of Polyvinylidene fluoride membrane 
(PVDF: Advanta: L-08008-001) was activated in methanol (Sigma: M3641).  Filter paper 
(Whatman) was trimmed to a size that fit the transfer apparatus.  A sandwich was prepared with 
a mesh, two pieces of filter paper, gel with protein, PVDF, two pieces of filter paper, and the 
final mesh. This sandwich was carefully generated ensuring no air bubbles would block current 
flow.  The sandwich was placed into the transfer tank and the tank placed into an ice-cold water 
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bath. Protein was transferred for 4 hours at 100 V (180 mA). Once the transfer was complete, the 
membrane was placed into a small box (protein side up) and Tween 20 in Tris buffered saline 
(TTBS: 0.5% Tween 20, 25 mM Tris, 150 mM NaCl, pH 7.2) added before the box was placed 
into the refrigerator (4°C).  
Probe membrane for Cx43: Non-fat dry milk (NFDM: Bio-Rad 170-6404) was added 
with TTBS to generating the Blocking solution (5% NFDM-TTBS).  The box, holding the 
membrane, was placed on a rocker (Boekel Scientific: Rocker II model 260350) at room 
temperature and the blocking solution was added (7 mL per membrane).  After 2 hours, the 
membrane was washed with TTBS before the Primary Ab solution [1% NFDM-TTBS with Cx43 
Ab (Sigma: C6219) at a 1:2000 ratio: 7 mL per membrane] was added. After 2 hours, the 
membrane was washed with TTBS and the Secondary Ab solution [1% NFDM-TTBS with a 
biotinylated goat anti-rabbit IgG (Invitrogen: A16100) at a 1:3500 ratio: 7 mL per membrane] 
was applied. After 2 hours, the membrane was washed with TTBS and the streptavidin HRP 
solution [1% NFDM-TTBS solution with streptavidin HRP (Thermo Scientific: PI 21130) at a 
1:4667 ratio: 7 mL per membrane] was added.  After 2 hours, the membrane was washed with 
TTBS followed by TBS and stored at 4°C until imaged.   
Chemiluminescence: The membrane was treated with the chemiluminescent substrate 
(Advansta: K12045) as indicated by the manufacturer and the membrane was imaged (UVP EC3 
Imaging System).  Pictures were taken at 20 second intervals and a summative image generated.  
The camera was stopped when the image showed signs of saturation.  The image with the 
greatest intensity signal (without saturation) was selected and converted into a JPG file and 
analyzed with ImageJ (freeware).  A background subtracted signal was determined by 
subtracting the intensity of a background image (close to the Cx43 band) from the 43 kDa band 
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itself.  The background subtracted signals for the ALA treated cells were normalized by the 
background subtracted control samples isolated at the same time.  In addition, background 
subtracted control samples were normalized to the background subtracted control sample at time 
zero. A ratio of 1 indicates the expression of Cx43 was not altered by the treatment. 
Statistical Analysis: The normalized data are reported as means and standard error of the 
means (SEM).  To address whether Cx43 expression was altered, Cx43 expression from each 
sample was compared to 1 with a single sample t test.  With use of the single sample t test, we 
can evaluate if there is a change in expression of the treated group as well as the control group. 
Significant differences between samples was set at P<0.05. 
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Chapter 4: Results 
ALA is an omega-3 FA which binds to the FFA-4 receptor (Hirasawa et al., 2005) to 
stimulate an anti-inflammatory response (Oh et al., 2014, and Cheshmehkani et al., 2015). As 
previous work in the lab showed the FFA-4 receptor was expressed on bEnd.3 cells (Rogers and 
Kurjiaka: personal commmunication), we expect physiological concentration of ALA (30 M) to 
decrease bEnd.3 cell expression of Cx43.  Representative results from a single experiment are 
presented in Figure 8. The intensity of the Cx43 signal for treated samples (+) was divided by the 
control sample isolated at the same time (-).  For this experiment, the ratios of Cx43 expression 
was close to 1 suggesting no change in expression.  Summary data in Figure 9a (n=6) support 
lack of change in Cx43 expression from 1.5 – 48 hours after treatment with 30 M ALA 
(p>0.05).  However, the SEM values indicate substantial variability between experiments. 
 
  
 
Figure 8: Western blot representative of Cx43 expression: 30 M stimulation.  The Cx43 signal from cells treated with ALA 
(+) was normalized to the Cx43 signal from control cells treated with 0.1% ethanol and isolated at the same time (-).  Changes in 
Cx 43 expression are indicated by a difference from 1.0 (Cx43 Expression (TRT)).  The values for each time were close to 1.  A 
comparison was also generated for controls to determine whether Cx43 expression changed over the 48-hour period (Cx43 
Expression (CNTL)).  The control Cx43 signal at each time point was normalized to time 0 (protein sample isolated as the 
experiment started). The controls show a reduction in Cx43 expression across the course of this experiment (Cx43 expression 
(CNT))  
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To determine whether Cx43 expression was decreased across the 48-hour experiment, 
Cx43 signal at each time was divided by the Cx43 signal from the sample isolated at the 
beginning of the experiment (time zero).  Interestingly, the values below 1 suggest the expression 
of Cx43 decreased over the 48-hour experiment.  This trend was supported by the summary data 
(Figure 9b).  While not significant due to the variability in the data (p>0.05), there was a trend 
towards a decrease in Cx43 expression across the course of the experiment.  Thus, the time 
controls were an essential part of this experiment. 
 
      A       B 
Figure 9: Summary of Cx43 expression after 30M ALA stimulation and controls. (A) Cx43 expression is the ratio of ALA 
treated to control: change is indicated by a difference from 1.  While there were small changes in Cx43 expression (elevated at 3 
hours and reduced at 12 and 48 hours), none of them reached significance (p>0.05). However, the relatively high SEM values 
means there was substantial variability.  (B) Cx43 expression in controls is the ratio of time control to time 0.  While not 
significant (p>0.05), there was a trend towards reduced Cx43 expression across the 48-hour experiment.  
 
As the data (Figure 9a) argue physiological concentrations of ALA did not affect Cx43 
expression, the concentration of ALA was increased to 100 M.  As previous work in the lab on 
other omega-3 FAs suggested the reductions in Cx43 expression would occur after 12 hours, the 
experiments evaluated Cx43 expression at 12, 24, and 48 hours.  Representative results (Figure 
10) suggest 100 M ALA may be decreasing Cx43 expression at 48 hours (0.86 in comparison to 
1.0: a decrease in Cx43 expression).  These data show similar reductions in Cx43 expression in 
control cells (0.77 in comparison to 1.0 at 48 hours: a decrease in Cx43 expression).  However, 
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summary data (n=7) indicated Cx43 expression was not altered by 100 M ALA (Figure 11a) 
and there was a similar trend towards a reduction in Cx43 expression in control experiments 
(Figure 11b). 
 
Figure 10: Western blot representative of Cx43 expression: 100 M stimulation.  Cells treated with ALA (+) were compared 
to cells from the control (-) group at the same time point. Changes in Cx43 expression were indicated by a difference from 1 
(Cx43 Expression (TRT)). The values for each time were close to 1, indicating little change in expression of Cx43 among all time 
points. Cx43 expression in control experiments showed a modest trend in decreased expression as time progressed (Cx43 
Expression (CNT)). 
 
 
          A                  B 
Figure 11: Summary of Cx43 expression after 100 M ALA stimulation and controls. (A) With respect to cells treated with 
higher ALA concentration, the ratios were not different from 1 (p>0.05) which argues Cx43 expression did not change. (B) Cx43 
expression from controls were evaluated to understand whether Cx43 expression changed during the experiment.  While not 
significant, the data show a trend towards decreased Cx43 expression (especially at 48 hours). 
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As our original hypothesis regarding the impact of ALA on Cx43 expression was not 
supported, we wanted to address a reason why our hypothesis was not supported by the data 
collected.  Previous work suggested ALA can bind to both the FFA-1 and FFA-4 receptors 
(Ichimura et al., 2014).  Although the FFA-4 receptor is present on bEnd.3 cells (Rogers and 
Kurjiaka: personal communication), there is no evidence of FFA-1 receptor presence in the 
bEnd.3 cells.  Although previous work argues FFA-1 receptor expression is localized to the 
intestines and pancreas (Hirasawa et al., 2005 and Ichimura et al., 2014), it is unclear whether 
this receptor could be expressed in other tissues, including bEnd.3 endothelial cells. Thus, we 
evaluated whether FFA-1 receptor responses could be generated in bEnd.3 cells by treating them 
with an FFA-1 receptor agonist GW-9508 (10 M).  While GW-9508 can bind to the FFA-4 
receptor, its affinity for FFA-1 receptor is 100X greater with an EC50 of 7.  A representative 
experiment of Cx43 expression after GW-9508 stimulation after 48 hours is shown in Figure 12.  
There was no difference in Cx43 expression of the control group compared to the treated group 
(1.09 in comparison to 1.0: no change in Cx43 expression), indicating ALA is not activating the 
pro-inflammatory FFA-1 receptor.  A summary of Cx43 expression in response to GW-9508 (48 
hour stimulation) is shown in Figure 13 (n=8).  Among all trials, Cx43 expression remained 
unchanged.  
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Figure 12: Western blot representative of Cx43 expression after GW-9508 stimulation. Cells treated with GW-9508 (+) 
were compared to cells from the control (-) group at 48 hours.  Neither the treated (TRT) nor the controls (CNT) appeared to have 
a change in Cx43 expression (close to 1). 
 
 
 
 
 
 
Figure 13: Summary of Cx43 expression after 10 M GW-9508 stimulation. GW-9508 is the FFA-1 receptor agonist.  
Change in expression of Cx43 is shown by being above or below the line representing 1.  There was no significant change 
(p>0.05) in Cx43 expression in response to GW-9508. 
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Chapter 5: Discussion 
As previous studies have shown omega-3 FAs (specifically EPA and DHA) bind to the 
FFA-4 receptor to reduce inflammation (Williams-Bey et al., 2014 and Oh et al., 2014), we 
investigated the impact of ALA on cultured endothelial cell.  When bEnd.3 cells were treated 
with 30 M ALA, expression of Cx43 was unaffected (Figs 1 and 2).  When ALA concentration 
was increased to 100 M, no change in Cx43 expression was observed out to 48 hours.  Since 
the FFA-4 receptor was present on bEnd.3 cells, the co-expression of the FFA-1 receptor might 
counter the anti-inflammatory responses to ALA. However, stimulation of the FFA-1 receptor 
agonist GW-9508 (10 M) did not alter Cx43 expression at 48 hrs.  Thus, the omega-3 FA ALA 
does not appear to affect endothelial cells expression of Cx43.  The interpretation of these results 
for endothelial cell function will be addressed below. 
Variability: 
 Cultured endothelial cells provide a convenient tool to evaluate the impact of specific 
molecules on endothelial cell function.  However, as with every other technique, there are 
potential confounding influences that impact the outcome of an experiment.  The data from 
figures 3 and 5 suggest a strong confounding influence: the effect of cell density on Cx43 
expression (confluency).  The expression of Cx43 increased initially and decreased through the 
duration of the experiment (especially at 24-48 hours).  While these changes were not significant, 
they point to the importance of matching the cell density between treated and time control 
samples.  If the control plates were not of a similar density (confluency) as the treated plates, 
they would not adequately control for the effect of time on Cx43 expression.  The 30 M ALA 
experiments were not performed in a way that controlled for this possibility (cells were not 
counted). For the 100 M ALA experiments, cells were plated evenly at 800,000 cells per plate 
 39 
and allowed to grow for 48 hours.  The reduction in SEM for the control data (Figure 11b) 
support the assertion that our techniques contributed to the variability in 30 M ALA data.  
However, the reduction in variability did not affect the outcome of the experiment as 100 M 
ALA did not affect Cx43 expression (Figure 11a).  The mechanism by which cell density 
impacts Cx43 expression is an avenue of investigation that would be interesting to address in the 
future.  
 The quantification of Cx43 expression relies on the equal concentration of protein in each 
well of the gel (i.e. from each sample).  An evaluation of a constitutively expressed control 
protein was not included in these experiments for financial reasons (cost of the antibodies).  
Thus, small errors in pipetting for the BCA assay or the preparation of samples for Western blot 
(2 g/L) could have affected the results of our experiments in ways we cannot account for.  In 
addition, the samples would have been concentrated if the lid was not sealed during the boiling 
of the samples.  Thus, future experiments should evaluate a constitutive expressed protein (i.e. 
tubulin) to allow correction of any equal protein loading errors.   
Impact of ALA on endothelial cells: 
While endothelial cells have many energy sources, ALA could also contribute to energy 
production via beta oxidation.   This use in energy production would decrease the ALA available 
to bind to the FFA-4 receptor.  However, endothelial cells do not seem to rely on FAs to provide 
the energy they require (Terramani et al., 2000 and Sawada et al., 2017).  FAs also have the 
capacity to enter the cell via a FA transport protein (Sawada et al., 2017).  Alternatively, 
endothelial lipases could assist the incorporation of ALA into the cell membrane (Kratky et al., 
2005). Once in the membrane, ALA alters membrane fluidity which can affect ion channel 
gating (Cordero-Morales et al., 2018) and gap junction communication (Puebla et al., 2017). 
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These alterations in channel function and cell-cell communication could be beneficial to the cell.  
However, once in the membrane, ALA could become a substrate for a cyclooxygenase (COX) or 
lipoxygenase (LOX) enzyme which convert FAs to prostaglandins (PG) or leukotrienes, 
respectively (Ding et al., 2003).  Interestingly, bEnd.3 cells express the COX-2 enzyme 
responsible for the synthesis of PGE2 from arachidonic acid (Lin et al., 2014).  The expression 
of COX 2 in these cells is upregulated by lipopolysaccharides (Chuang et al., 2014) that can 
stimulate an inflammatory response. The increase in ALA in these cells could become a direct 
COX-2 substrate and produce PGE3. Prostaglandins themselves can alter Cx43 expression (Qin 
et al., 2016): PGE2 increases Cx43 expression (Yun et al., 2012) while PGF2 decreases Cx43 
expression (Xu et al., 2014).  Thus, the lack of change in Cx43 in the bEnd.3 cells could reflect 
the combined effects of ALA on the FFA-4 receptor along with ALAs conversion to 
prostaglandins.   
While the preponderance of epidemiological evidence argues omega-3 FA have anti-
inflammatory effects (Adkins et al., 2010, Collie-Duguid et al., 1996, and Kris-Etherton et al., 
2002), individual studies addressing the mechanisms by which these effects are mediated have 
not always support this conclusion.  In the case of the FFA-4 receptor, some have argued they do 
not mediate anti-inflammatory responses (Pærregaard et al., 2016). The FFA-4 receptor is a G-
protein coupled receptor that usually turns off very quickly once activated.  Previous work from 
the lab argued any anti-inflammatory effect from the omega-3 FAs occurred 12-48 hours after 
the responses were initiated (Sundblad and Kurjiaka and Pageau and Kurjiaka: personal 
communications).  These data do not fit the time course expected for a G-protein coupled 
response.  Rather, they appear more like a prostaglandin response.  The synthesis of 
prostaglandin from ALA would require enough time to increase to a concentration that would 
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alter Cx43 expression.  In addition, the PPAR-alpha, PPAR-gamma, and/or PPAR-beta/delta 
pathway, could be involved in the response to omega-3 FAs (Ringseis et al., 2010 and Adkins et 
al., 2010).  PPAR-alpha, PPAR-gamma, and PPAR-beta/delta are ligand activated transcription 
factors that are important regulators for lipoprotein metabolism and inflammation (Ringseis et 
al., 2010).  Poly-unsaturated FAs, including omega-3 FAs, along with prostaglandins activate 
these PPAR receptors and elicit an anti-inflammatory, anti-atherogenic response (Marx, 2004).  
Whether the PPAR receptor is expressed (and more importantly activated) in the bEnd.3 cell has 
yet to be addressed. 
 Inflammation is a disease where the cytokines released alters the expression of many cell 
surface proteins and transcription factors.  Cx43 gap junction protein is a cell surface protein 
altered by NF-κB.  However, Cx43 expression can also be altered by factors unrelated to 
inflammation (i.e. cell confluency, oxidative stress (Madamanchi, 2004), and hypoxia (Wu et al., 
2013)).  As the only protein evaluated in this study was Cx43, assessment of additional 
endothelial cell markers of inflammation such as VCAM or direct assessment of NF-B would 
strengthen the outcome of future experiments.   
Summary: 
 The data collected in the experiments above suggest there is no anti-inflammatory effect 
of ALA on endothelial cells.  While this is not what was expected, this study should not reduce 
our ALA consumption.  There are several confounding variables that have made the study of 
FAs very challenging (prostaglandin synthesis, PPAR activation, energy storage, etc.).  Based 
upon the study design, the possibility that ALA might still be anti-inflammatory cannot be 
eliminated (evaluation of different markers of inflammation). This result should redouble our 
efforts to understand the role of FAs in human health and disease.  The FFA-4 receptor may still 
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be part of the anti-inflammatory response in the vasculature, and body in general, as there is 
much interest in the use of omega-3 FA to impact other inflammatory disease processes. 
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